Madrigal Pharmaceuticals, Inc. Stock News
$212.43
0.69%
yesterday
Nasdaq,
Sep 27, 10:00 pm CET
Madrigal Pharmaceuticals, Inc. Stock News
Positive
The Motley Fool
●
about one month ago
Madrigal Pharmaceuticals earned the first approval for a medicine in an area with a high unmet need. The biotech has more to do to dominate this market, considering it should become more crowded soon.
Neutral
The Motley Fool
●
about one month ago
Novo Nordisk just canceled one of its early-stage clinical programs. Madrigal Pharmaceuticals is a specialist developer for the same target illness.
Positive
Seeking Alpha
●
about 2 months ago
Madrigal Pharmaceuticals' Q2 2024 revenue from Rezdiffra exceeded expectations at $14.6 million. The company's SG&A expenses surged to $105.4 million, reflecting launch activities. Over 2,000 patients are currently on Rezdiffra, with broad insurance coverage.
Neutral
Seeking Alpha
●
about 2 months ago
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q2 2024 Results Conference Call August 7, 2024 8:00 AM ET Company Participants Tina Ventura - Chief Investor Relations Officer Bill Sibold - CEO, President & Director Mardi Dier - CFO & Senior VP Conference Call Participants Thomas Smith - Leerink Partners Andrea Tan - Goldman Sachs Andy Chen - Wolfe Research Eliana Merle - UBS Yasmeen Rahimi - Pipe...
Neutral
GlobeNewsWire
●
about 2 months ago
CONSHOHOCKEN, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today reports second-quarter 2024 financial results and provides corporate updates.
Positive
The Motley Fool
●
about 2 months ago
Madrigal Pharmaceuticals is launching its first medicine. It's also the first competitor to enter its market.
Neutral
GlobeNewsWire
●
about 2 months ago
CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024.
Neutral
GlobeNewsWire
●
2 months ago
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
